Dare Bioscience, Inc. DARE Cash Flow

Dare bioscience, inc. (DARE)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities:
Operating activities:
Net loss
-4,252	-	-3,393	-3,952	-3,051	-	-2,574	-3,582	-7,665	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income (Loss) Attributable to Parent
-	-	-	-	-	-	-	-	-	-	-	5,596	-6,339	33,687	-33,903	13,085	-13,542	10,495	-10,551	-9,907	-8,428	-7,467	-5,558	-7,403	-2,914
Non-cash adjustments reconciling net loss to operating cash flows:
Depreciation
11	7	1	1	1	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
160	117	135	111	97	80	39	9	9	8	6	-905	906	-2,148	2,157	-740	741	-834	835	456	440	257	285	195	148
Non-cash operating lease cost
-55	-39	0	10	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncash rent expense
-	-	-	-	-	-	-	-	-	-	-	-	10	-	-	-	124	-17	-11	-7	-6	-4	31	0	2
Change in carrying value of preferred stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-504
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	66	-	-	-	61	63	46	42	41	33	30	27	36
Amortization of debt discount and deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	610	-	-	-	127	-281	229	276	515	-	-	-	-
Loss on disposal of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-	-	-	-	-	-	-	-
Impairment of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	102	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-625	-	-	-	-	-	-	-	-	-	-	-	-
Gain on asset sale
-	-	-	-	-	-	-	-	-	-	-	-	1,500	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	109	120
Impairment of goodwill
-	-	-	-	-	0	0	-12	5,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Other receivables
-125	194	-455	326	135	-49	55	-4	-255	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,019
Prepaid expenses
2,736	-44	332	-166	201	-146	202	56	-20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	0	0	0	-193	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current assets
-38	-	-59	-23	-55	-	-39	-29	-37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-157	347	-652	120	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	316	-	-	-	18	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	1,039	-	-	-	174	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-49	50	-40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
448	-	-	-	-134	-	-	-	-	-	-	1,352	-802	270	-274	-137	141	-387	401	125	378	-206	882	-1,581	1,246
Accrued expenses
-408	-283	194	650	59	-303	-12	407	-118	-	-	-	-1,073	-	-	-	-724	2,047	1,431	566	-761	1,623	-539	1,116	-781
Deferred grant funding
930	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred license revenue
1,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	8	-2	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-6,597	-3,808	-3,206	-2,991	-3,308	-2,710	-2,750	-2,688	-2,118	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	9,839	-10,000	31,288	-31,478	13,077	-13,260	7,678	-7,967	-7,797	-7,941	-5,608	-5,558	-4,229	-3,666
Investing activities:
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	359	136	34	78	29	109	78	24	14
Financing activities:
Net proceeds from issuance of common stock
5,222	-	0	5,151	0	-	-81	-2	10,197	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	30	10
Decrease in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-117	-	-	-	-	-	-	-	-
Proceeds from the sale of assets
-	-	-	-	-	-	-	-	-	-	-	-	1,500	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-1,500	1,500	382	-382	242	-242	34	-34	-308	-29	-109	-78	6	-4
Financing activities:
Proceeds from the exercise of common stock warrants
1,665	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	62	-	-	-	41	-148	156	61	2,411	0	7	106	27
Proceeds from loan payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,000	0	0	15,000	-	-	-	-
Proceeds from issuance of convertible promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8,500
Net cash provided by financing activities
6,887	0	0	5,151	0	-2	-81	-2	10,197	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-22	-	-15	-7	7	-	-18	-27	-13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
267	2,344	-3,195	2,125	-3,300	-2,731	-2,909	-3,178	8,065	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on loan payable
-	-	-	-	-	-	-	-	-	-	-	-	13,077	-	-	-	1,932	-600	0	0	3,921	862	846	828	812
Cash paid for debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	359	-	-	-	-
Payment of end of term charge on loan payable
-	-	-	-	-	-	-	-	-	-	-	-	1,407	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	-	-	-	1,065
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	14,577	-14,422	-	-	-	-1,891	352	156	37,265	13,112	-895	-849	60,026	6,650
Net change in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-22,922	-	-	-	-15,393	-1,723	-7,845	29,160	5,142	-6,612	-6,485	55,803	2,980
Supplemental disclosure of non-cash operating and financing activities:
Operating right-of-use assets obtained in exchange for new operating lease liabilities
0	351	0	0	231	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental cash flow information Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	269	-	-	-	372	277	280	280	163	74	92	108	126